What the SREBP-1c Antibody Detects
The SREBP-1c antibody is a research reagent raised against Sterol Regulatory Element-Binding Protein 1c, a transcription factor central to lipid metabolism. In Western blots, immunohistochemistry, and immunofluorescence, the antibody recognizes the SREBP-1c protein, allowing researchers to track its expression, processing, and nuclear translocation. Most commercial clones target an epitope within the N-terminal bHLH domain or the full-length precursor, and the expected band size is approximately 115–125 kDa for the precursor and roughly 68 kDa for the active N-terminal fragment after proteolytic cleavage.
More from this site
Keep reading the latest coverage
Because SREBP-1c is a member of the SREBP family — alongside SREBP-1a and SREBP-2 — antibody specificity is a primary concern. A well-validated SREBP-1c antibody should not cross-react significantly with SREBP-1a or SREBP-2, though researchers should confirm this in their own experimental context, particularly when comparing isoforms in liver or adipose tissue lysates.
Biological Role of SREBP-1c
SREBP-1c is a master regulator of de novo lipogenesis. In the fasted state, it is retained in the endoplasmic reticulum membrane bound to SCAP and Insig proteins. When cellular sterol levels fall or when insulin signaling rises, the SREBP-1c/SCAP complex moves to the Golgi, where Site-1 and Site-2 proteases cleave the transcription factor. The released N-terminal domain enters the nucleus and activates genes such as FASN, ACC1, SCD1, and fatty acid synthase, driving triglyceride and cholesterol ester synthesis.
In the liver, insulin potently induces SREBP-1c mRNA, linking fed-state signaling to lipogenic gene expression. In adipose tissue, SREBP-1c supports adipocyte differentiation and triglyceride storage. Dysregulation of SREBP-1c is implicated in nonalcoholic fatty liver disease, insulin resistance, and obesity, making it a frequently studied target in metabolic disease models.
Common Research Applications
Researchers use the SREBP-1c antibody in several standard workflows:
- Western blot — to assess total SREBP-1c levels and the ratio of precursor to active fragment under different metabolic conditions.
- Immunohistochemistry — for tissue localization, particularly in liver biopsy sections or mouse adipose sections, where SREBP-1c nuclear staining correlates with active lipogenesis.
- Immunofluorescence — to monitor subcellular redistribution, typically from the ER membrane to the nucleus after insulin or cholesterol depletion treatment.
- Chromatin immunoprecipitation (ChIP) — some antibodies support ChIP-seq to map SREBP-1c binding at lipogenic gene promoters.
Validation and Clone Selection
Not all SREBP-1c antibodies perform equally across applications. When choosing a clone, consider the following:
- Application validation — confirm the supplier lists data for your intended use (WB, IHC, IF, IP).
- Epitope location — antibodies against the N-terminal domain detect only the active fragment; antibodies against the C-terminus or full-length protein detect both precursor and processed forms.
- Species reactivity — most clones work in human, mouse, and rat, but verify the species table before ordering.
- Isotype and conjugate — unconjugated antibodies are required for most protocols, while conjugated forms (HRP, FITC, Alexa Fluor) suit direct detection.
Positive controls typically include liver cell lines treated with insulin or cholesterol-depleting agents, and peptide competition assays can confirm specificity.
Biological Context and Disease Relevance
Because SREBP-1c sits at the intersection of insulin signaling and lipid synthesis, its antibody is a tool for studying metabolic homeostasis. In NAFLD/NASH research, elevated nuclear SREBP-1c in hepatocytes correlates with steatosis. In diabetes models, SREBP-1c overactivation contributes to hepatic lipid accumulation and impaired insulin sensitivity. The antibody therefore supports both basic mechanism studies and translational research, though it is strictly an in vitro and tissue-level reagent — it is not a diagnostic or therapeutic agent.
Summary
The SREBP-1c antibody enables detection and quantification of a key lipogenic transcription factor across multiple research applications. Selecting a well-validated clone, confirming specificity against family members, and pairing the antibody with appropriate positive controls will yield the most reliable data in studies of lipid metabolism and metabolic disease.